Frontiers in medicine · 2026
Factors associated with de novo urolithiasis after kidney transplantation: a matched case-control study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tian Wenshi, Zhang Zhengyang, Chen Hao, Wang Xulei, Jiang He, Liu Kai, Chen Dongdong, Shen Bin, Yang Jiwei, Li Xianduo, Zhang Xiaoming, Wang Yunchao, Wang Jianning
Аннотация
OBJECTIVE: To investigate the clinical characteristics and potential risk factors for de novo urolithiasis in recipients after kidney transplantation.
METHODS: We retrospectively screened a source cohort of 2,301 kidney transplant recipients undergoing longitudinal follow-up between January 2015 and December 2025. Forty recipients who developed de novo post-transplant urolithiasis were identified. For each recipient who developed a stone, the date of first stone diagnosis was defined as the index date. Controls who had undergone transplantation and remained under follow-up without detected stones at the corresponding index date were selected using chronological risk-set matching at a maximum 1:2 ratio. Thirty-seven cases were matched to 74 controls. Laboratory exposures were summarized using available baseline/pre-index measurements. Covariate balance was assessed using standardized mean differences (SMDs). The primary analysis used conditional logistic regression, with Firth bias-reduced conditional logistic regression as a sensitivity analysis.
RESULTS: Among 2,301 recipients, 40 developed de novo post-transplant urolithiasis, corresponding to an observed cumulative proportion of 1.74%. The median time from transplantation to first stone diagnosis was 341.5 days (interquartile range, 41.0-1,931.5 days). After risk-set matching, excellent covariate balance was achieved across all matched variables (maximum absolute SMD = 0.037). Standard conditional logistic regression revealed that higher baseline serum urate was significantly associated with an increased risk of de novo urolithiasis [odds ratio (OR) 1.72 per 50 μmol/L increase, 95% CI 1.17-2.54; P = 0.006], whereas higher serum phosphate exhibited an inverse association (OR 0.77 per 0.1 mmol/L increase, 95% CI 0.62-0.95; P = 0.016). Firth sensitivity analysis confirmed these findings for serum urate (OR 1.64, 95% CI 1.13-2.38; P = 0.009) and serum phosphate (OR 0.79, 95% CI 0.65-0.97; P = 0.025). Urinary white blood cell (WBC) count showed a strong exploratory association (OR 2.71 per log2 doubling, 95% CI 1.59-4.63; P < 0.001), though the model exhibited near-separation.
CONCLUSIONS: Elevated serum urate is consistently associated with an increased risk of de novo urolithiasis following kidney transplantation. Lower serum phosphate represents a potential secondary metabolic signal requiring further validation. While urinary leukocyturia strongly correlated with stone status in exploratory models, it should be interpreted cautiously and not regarded as a definitive causal factor or surrogate for culture-confirmed urinary tract infection.
METHODS: We retrospectively screened a source cohort of 2,301 kidney transplant recipients undergoing longitudinal follow-up between January 2015 and December 2025. Forty recipients who developed de novo post-transplant urolithiasis were identified. For each recipient who developed a stone, the date of first stone diagnosis was defined as the index date. Controls who had undergone transplantation and remained under follow-up without detected stones at the corresponding index date were selected using chronological risk-set matching at a maximum 1:2 ratio. Thirty-seven cases were matched to 74 controls. Laboratory exposures were summarized using available baseline/pre-index measurements. Covariate balance was assessed using standardized mean differences (SMDs). The primary analysis used conditional logistic regression, with Firth bias-reduced conditional logistic regression as a sensitivity analysis.
RESULTS: Among 2,301 recipients, 40 developed de novo post-transplant urolithiasis, corresponding to an observed cumulative proportion of 1.74%. The median time from transplantation to first stone diagnosis was 341.5 days (interquartile range, 41.0-1,931.5 days). After risk-set matching, excellent covariate balance was achieved across all matched variables (maximum absolute SMD = 0.037). Standard conditional logistic regression revealed that higher baseline serum urate was significantly associated with an increased risk of de novo urolithiasis [odds ratio (OR) 1.72 per 50 μmol/L increase, 95% CI 1.17-2.54; P = 0.006], whereas higher serum phosphate exhibited an inverse association (OR 0.77 per 0.1 mmol/L increase, 95% CI 0.62-0.95; P = 0.016). Firth sensitivity analysis confirmed these findings for serum urate (OR 1.64, 95% CI 1.13-2.38; P = 0.009) and serum phosphate (OR 0.79, 95% CI 0.65-0.97; P = 0.025). Urinary white blood cell (WBC) count showed a strong exploratory association (OR 2.71 per log2 doubling, 95% CI 1.59-4.63; P < 0.001), though the model exhibited near-separation.
CONCLUSIONS: Elevated serum urate is consistently associated with an increased risk of de novo urolithiasis following kidney transplantation. Lower serum phosphate represents a potential secondary metabolic signal requiring further validation. While urinary leukocyturia strongly correlated with stone status in exploratory models, it should be interpreted cautiously and not regarded as a definitive causal factor or surrogate for culture-confirmed urinary tract infection.